Adenosine Discovered as a Novel Agonist for Growth Hormone Secretagogue Receptor
Background
The growth hormone secretagogue receptor (GHSR), primarily known for binding the hunger hormone ghrelin, plays a critical role in regulating growth hormone (GH) release, appetite, and metabolism. While ghrelin is the only known endogenous ligand, the existence of other natural activators has long been hypothesized, potentially offering alternative regulatory pathways for GH secretion and energy homeostasis. This study addresses the specific knowledge gap regarding other endogenous molecules that might activate GHSR.
Results
The study revealed that adenosine acts as a direct agonist of the GHSR1a receptor, inducing robust intracellular signaling pathways in a dose-dependent manner. Adenosine significantly increased intracellular calcium levels, demonstrating an EC50 of approximately 500 nM, indicating potent activation. This activation was comparable to the known agonist ghrelin at similar concentrations, achieving 85% of ghrelin's maximal effect on calcium mobilization. Furthermore, pre-treatment with a specific GHSR antagonist completely blocked adenosine's effects, confirming that its action was mediated directly through the GHSR1a receptor. ERK phosphorylation, another indicator of receptor activation, also showed a 2.5-fold increase with adenosine treatment compared to control. The study unequivocally demonstrated that adenosine is a novel, direct agonist of the growth hormone secretagogue receptor (GHSR1a), capable of initiating significant downstream signaling.
Why It Matters
This discovery fundamentally expands our understanding of GHSR regulation beyond ghrelin, suggesting a broader physiological role for this receptor. It implies that adenosine, a ubiquitous signaling molecule involved in energy metabolism and neuromodulation, could play a previously unrecognized role in growth hormone (GH) secretion, appetite control, and metabolic processes. <u>This finding opens new avenues for developing novel therapeutic strategies targeting GHSR for conditions such as growth hormone deficiency, metabolic disorders, or even cachexia</u>. Future research should focus on in vivo validation in animal models to elucidate adenosine's physiological role in GH regulation and explore its potential as a therapeutic target.